

INTERNATIONAL CONSORTIUM FOR GENETIC TESTING IN ALS/MND INDUSTRY PARTNER ROUNDTABLE

Day 1 – Tuesday, September 28th, 2021
(all times listed are in EST)

7:00 am	Welcome
7:10 am	International Consortium for Genetic Testing in ALS <ul style="list-style-type: none"> • Overview • Objectives & planned outcomes
7:20 am	Industry Partners – roundtable introductions (3-5 minutes each) <ul style="list-style-type: none"> • Therapeutic pipeline for genetic ALS (targets & pipeline status) • Other interest/priorities
8:15 am	International Alliance of ALS/MND Associations
8:25 am	<i>Break</i>
8:35 am	Key topics of discussion <ul style="list-style-type: none"> • Timely access to & coordination of: genetic counselling, testing & treatment administration • Availability of commercial/CLIA genetic testing • Companion diagnostics • Natural history data • Risk factor vs. causative genes • Mutation Adjudication • Targeted (e.g. A4V) vs. Broad (e.g. all SOD1) therapies
9:55 am	Closing remarks & plan for Day 2

Day 2 – Wednesday, September 29th, 2021
(all times listed are in EST)

7:00 am	Welcome
7:10 am	Recap from Day 1 <ul style="list-style-type: none"> • Highlights & themes from the roundtable discussion
7:30 am	Areas of alignment & collaboration <ul style="list-style-type: none"> • Facilitated discussion
8:20 am	<i>Break</i>
8:30 am	Areas of alignment & collaboration (continued)
9:20 am	Communications strategy
9:45 am	Closing remarks & action items